ESSENCE trial results: Breaking new ground

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. E18, 1998, Pages

  Demers, Christine ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Enoxaparin; ESSENCE trial; Low molecular weight heparin; Non Q wave myocardial infarction; Unfractionated heparin; Unstable angina

Indexed keywords

ENOXAPARIN; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ADULT; ANGINA, UNSTABLE; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES;

EID: 0032135436     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cairns JA, Singer J, Gent M, et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1989;5:239-46.
2. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
3. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
4. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end-points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994;89:81-8.
5. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
6. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-5.
7. Lane DA. Heparin binding and neutralizing proteins. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications. Boca Raton: CRC Press, 1989:363-91.
8. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
10. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
11. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994;71:300-4.
12. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
13. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
14. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
15. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation 1997;96:61-8.
16. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events Study Group. N Engl J Med 1997;337:447-52.